{"filing":{"accession_number":"0001193125-26-428302","cik":"0001572616","ticker":"GUTS","company_name":"FRACTYL HEALTH, INC.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-21","primary_document":"guts-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1572616/000119312526428302/guts-20261021.htm"},"events":[{"id":37014,"run_id":34116,"accession_number":"0001193125-26-428302","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"Fractyl Health adopted a plan on October 21, 2026 to reduce its workforce by approximately 45% of current headcount, with estimated severance and termination costs of approximately $2 million to be incurred primarily in Q4 2026. The reduction is part of a strategic reprioritization to focus on the Revita program and is expected to reduce quarterly cash burn by approximately 50% to approximately $8 million by end of Q2 2027.","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41592,"accession_number":"0001193125-26-428302","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Fractyl Health adopted a plan on October 21, 2026 to reduce its workforce by approximately 45% of current headcount, with estimated severance and termination costs of approximately $2 million to be incurred primarily in Q4 2026. This is a material operational restructuring disclosed under Item 2.05 (Costs Associated with Exit or Disposal Activities), directly matching the workforce_reduction event type. The reduction is part of a strategic reprioritization to focus on the Revita program and is expected to reduce quarterly cash burn by approximately 50%.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"","ticker":null,"filing_date":""},{"id":41594,"accession_number":"0001193125-26-428302","item_number":"8.01","item_title":"Other Events.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material workforce reduction of approximately 45% to be substantially completed by November 2026, with expected quarterly cash burn reduction of ~50% to approximately $8 million by end of Q2 2027. While the press release also mentions Jay Caplan's retirement and discontinuation of the Rejuva program, the principal disclosed action centers on the workforce reduction and associated operational restructuring to focus resources on Revita. The reduction is material to investors as it reflects a significant strategic pivot and impacts the company's financial runway and operational capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37015,"run_id":34116,"accession_number":"0001193125-26-428302","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"Jay Caplan, Co-Founder, President and Chief Product Officer, announced his retirement effective October 30, 2026, with severance benefits and a planned consulting arrangement.","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":41593,"accession_number":"0001193125-26-428302","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"Jay Caplan, Co-Founder, President and Chief Product Officer, announced his retirement effective October 30, 2026. While the filing also discloses Harith Rajagopalan's appointment as President, the principal action disclosed is Caplan's departure from his executive roles. The filing explicitly states \"Jay Caplan announced his retirement\" and describes his separation in detail, including severance benefits and a planned consulting arrangement. Although both a departure and appointment occur, the prose centers on Caplan leaving his executive positions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41592,"accession_number":"0001193125-26-428302","item_number":"2.05","item_title":"Costs Associated with Exit or Disposal Activities.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Fractyl Health adopted a plan on October 21, 2026 to reduce its workforce by approximately 45% of current headcount, with estimated severance and termination costs of approximately $2 million to be incurred primarily in Q4 2026. This is a material operational restructuring disclosed under Item 2.05 (Costs Associated with Exit or Disposal Activities), directly matching the workforce_reduction event type. The reduction is part of a strategic reprioritization to focus on the Revita program and is expected to reduce quarterly cash burn by approximately 50%.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-10-22"},{"id":41593,"accession_number":"0001193125-26-428302","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"Jay Caplan, Co-Founder, President and Chief Product Officer, announced his retirement effective October 30, 2026. While the filing also discloses Harith Rajagopalan's appointment as President, the principal action disclosed is Caplan's departure from his executive roles. The filing explicitly states \"Jay Caplan announced his retirement\" and describes his separation in detail, including severance benefits and a planned consulting arrangement. Although both a departure and appointment occur, the prose centers on Caplan leaving his executive positions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-10-22"},{"id":41594,"accession_number":"0001193125-26-428302","item_number":"8.01","item_title":"Other Events.","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material workforce reduction of approximately 45% to be substantially completed by November 2026, with expected quarterly cash burn reduction of ~50% to approximately $8 million by end of Q2 2027. While the press release also mentions Jay Caplan's retirement and discontinuation of the Rejuva program, the principal disclosed action centers on the workforce reduction and associated operational restructuring to focus resources on Revita. The reduction is material to investors as it reflects a significant strategic pivot and impacts the company's financial runway and operational capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-22T11:03:50.886324+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-10-22"}]}